Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses. - sprookjes - yvandenbroek - TriplyDB

Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses.

Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses.

http://www.wikidata.org/entity/Q30531601

about

Biology of adeno-associated viral vectors in the central nervous system Synthetic biology and therapeutic strategies for the degenerating brain: Synthetic biology approaches can transform classical cell and gene therapies, to provide new cures for neurodegenerative diseases Intrabodies as neuroprotective therapeutics Carbidopa-based modulation of the functional effect of the AAV2-hAADC gene therapy in 6-OHDA lesioned rats Benefits of Neuronal Preferential Systemic Gene Therapy for Neurotransmitter Deficiency Axonal transport of AAV9 in nonhuman primate brain.Treatment of congenital neurotransmitter deficiencies by intracerebral ventricular injection of an adeno-associated virus serotype 9 vector.Adenosine kinase, glutamine synthetase and EAAT2 as gene therapy targets for temporal lobe epilepsy.Biodistribution of adeno-associated virus serotype 9 (AAV9) vector after intrathecal and intravenous delivery in mouse Systemic delivery of MeCP2 rescues behavioral and cellular deficits in female mouse models of Rett syndrome Pre-immunization with an intramuscular injection of AAV9-human erythropoietin vectors reduces the vector-mediated transduction following re-administration in rat brain SAFETY AND TOLERABILITY OF MRI-GUIDED INFUSION OF AAV2-hAADC INTO THE MID-BRAIN OF NON-HUMAN PRIMATE.Gene therapy for the nervous system: challenges and new strategies.Clinical applications involving CNS gene transfer.Transfection of brain capillary endothelial cells in primary culture with defined blood-brain barrier properties Inhibition of pathological brain angiogenesis through systemic delivery of AAV vector expressing soluble FLT1.A Single Injection of Recombinant Adeno-Associated Virus into the Lumbar Cistern Delivers Transgene Expression Throughout the Whole Spinal Cord.Selective Manipulation of Neural Circuits Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates.Gene therapy for misfolding protein diseases of the central nervous system.Continuous DOPA synthesis from a single AAV: dosing and efficacy in models of Parkinson's disease.Widespread AAV1- and AAV2-mediated transgene expression in the nonhuman primate brain: implications for Huntington's disease.Gene Therapy for the Treatment of Neurological Disorders: Metabolic Disorders.Prefrontal cortical dysfunction after overexpression of histone deacetylase 1.Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice.Adeno-associated virus type 6 is retrogradely transported in the non-human primate brain.Impact of age and vector construct on striatal and nigral transgene expression.AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction.Platelet gene therapy by lentiviral gene delivery to hematopoietic stem cells restores hemostasis and induces humoral immune tolerance in FIX(null) mice.Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in Huntington's disease mice.A next step in adeno-associated virus-mediated gene therapy for neurological diseases: regulation and targeting.Adeno-associated virus vectors and neurological gene therapy.Targeted delivery of miRNA therapeutics for cardiovascular diseases: opportunities and challenges.Distribution of nanoparticles throughout the cerebral cortex of rodents and non-human primates: Implications for gene and drug therapy.Viral vectors for therapy of neurologic diseases.Destination Brain: the Past, Present, and Future of Therapeutic Gene Delivery.Overview on Research and Clinical Applications of Optogenetics.Cell-Specific Targeting of Genetically Encoded Tools for Neuroscience.MR-guided parenchymal delivery of adeno-associated viral vector serotype 5 in non-human primate brain.Slow AAV2 clearance from the brain of nonhuman primates and anti-capsid immune response.

P2860

Q21129328-19EF2A63-7B9A-4F35-9AAA-FE389A582201 Q26830610-EE35A01C-0352-4692-842F-AE3EFAB51765 Q27003896-48A49CD0-8F12-498C-8153-ADC7B1311FCD Q27310170-0F3C631A-60A0-4B4E-9A8A-42B0B82D4594 Q27318185-0E96C6F3-C0A4-4944-A0C7-1368D4671741 Q27323331-EA76412B-EC11-475A-ACCA-062CD2F41DA8 Q30574128-DC1728C9-023D-42B7-B98E-4F0DE22A9FCA Q30605561-2901FFBC-7311-4886-A82C-5F127BC9004A Q33732656-5B3324CD-4519-4FBF-A968-6EB07B0A8FA3 Q34365749-D1BA4EC7-DDAD-4853-A71B-775E095D327A Q34718452-D096F513-BAE7-4A69-8312-40CA5BE3E8A9 Q34762396-410A2CAC-9223-400F-95DD-A89233E46F4D Q35340196-0D1B452F-EADA-4DC8-AE13-456CB811A5EF Q35899850-D0E9A2A8-47AD-4D91-8911-46166C125676 Q35923032-A0C728B0-C494-47DE-947E-503BA25C3292 Q36258054-6C1382E8-0CAE-4B09-AB05-7D7CC211A6F4 Q36352399-FDA091D7-ED36-438C-80A0-55E44F402C6A Q36775253-C4F7C17C-4779-4EFB-8C04-17B33F5016E7 Q36848703-5549C673-F8FB-4C46-8764-BF51E38949E7 Q36983203-8682423F-6593-4ED5-B071-D245F6F0E9BE Q36989384-13C0D378-2F2A-4ACC-915A-CA66FD792FD8 Q37051728-3BBB5728-EAEF-410A-8E0F-0709D78EE4C8 Q37127238-084E226A-5C41-4D52-8925-7D911AB0C7E8 Q37230971-8BB05722-A089-419F-865B-46957086DBC1 Q37237181-EB433979-E260-4D8E-9540-35E12222A0EE Q37374468-ECAE0E75-7574-4BBA-922B-84DC4F220229 Q37481547-F328D5C5-E1EB-449C-A7F9-E9337B027E6C Q37571781-06887BEA-7534-4AAD-803E-14946C32274C Q37690441-95BB9074-34A4-47E8-A697-9FFE18DD7854 Q37696030-D3F246B0-AB5A-487B-AF32-E66953DA1461 Q38075068-4F23F240-BF86-4DF5-A564-90B01D96F8C9 Q38190041-45BB534C-9675-409A-9CC5-12C0DA037FBD Q38217461-4F675F1B-1716-4BDC-809C-CAAF6D385781 Q38294647-370B05DE-90AA-41BD-9E5A-70779CCC815C Q38746238-D1F74D9F-32F9-4B08-AE47-EF266474743F Q38761724-B48A0DB6-65AB-4171-AD3C-5A7120E949BB Q38783461-2E708280-695A-47B6-85E4-430EA0AD2FDC Q38812342-2961E6EE-7D25-4A22-AA41-9B8695956F13 Q38903989-0414383B-11CD-401C-A448-1B781DBC51A0 Q40383175-AEDB08B9-67EA-4B5D-8B83-74281D77C1D3

P2860

Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses.

http://www.wikidata.org/entity/Q30531601

description

2012 nî lūn-bûn

@nan

2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Cerebral infusion of AAV9 vect ...... ell-mediated immune responses.

@ast

Cerebral infusion of AAV9 vect ...... ell-mediated immune responses.

@en

type

label

Cerebral infusion of AAV9 vect ...... ell-mediated immune responses.

@ast

Cerebral infusion of AAV9 vect ...... ell-mediated immune responses.

@en

prefLabel

Cerebral infusion of AAV9 vect ...... ell-mediated immune responses.

@ast

Cerebral infusion of AAV9 vect ...... ell-mediated immune responses.

@en

P1433

Q30531601-E0585DD8-B74B-479D-B1EA-1FAEEEE9ADB1

P1476

Q30531601-18AD6EA0-3001-4078-AC2A-906215FD50B3

P2093

Q30531601-308921E4-B80F-4DD1-A034-B955D4B86982

Q30531601-3BF36D5D-AF90-4485-913E-4C237014B21C

Q30531601-4F4D3C79-82A6-4525-85FA-1808A45ED883

Q30531601-5908B8F5-A93E-4030-A536-3B5D385B2091

Q30531601-89AE731B-D37E-4C40-A25C-FA199E451AE6

Q30531601-8AF9B5A7-1147-4A08-88AC-29E7C2FF18BA

Q30531601-9E8F1765-86CE-4DA5-910F-062186BDA71B

P2860

Q30531601-062A36EA-D8EA-46BC-8DDB-DA9C858C7640

Q30531601-07B14C58-17CF-4CBC-B658-6FDCFA0EF92C

Q30531601-0E8BB274-8853-437B-9B75-999ED9A0B547

Q30531601-0F9D78C8-F8F6-4825-BF5A-4D8AA4673E41

Q30531601-1E91B049-35D2-4D11-A52D-99701B60E1F1

Q30531601-21111146-DAE6-488B-BB09-CA3E595AFF0C

Q30531601-355568AE-5205-45AD-A156-2B8AF521A166

Q30531601-424A36BB-4E5C-493A-B6CE-54F3D2BD7F39

Q30531601-46118382-91F9-479D-A47E-0D9955A42E6D

Q30531601-5159CCBD-FE64-43C7-ABF6-A06272851DAC

P304

Q30531601-4C39020C-B88A-4C72-8CD2-A6E7695C5F61

P31

Q30531601-BFD475DF-BD4A-41AF-B89B-E945CB35AE12

P356

Q30531601-A4CDD55F-4812-4756-8BAB-47A322B86D18

P433

Q30531601-E7C3702C-28D9-47C9-86D1-249B3B47287F

P478

Q30531601-444EFA6C-20F2-447E-BD48-83A026102555

P577

Q30531601-783F2129-32D0-4336-A0F7-B792D6BF5EDF

P5875

Q30531601-5146843E-0709-4881-8A05-7D1AF3E2F78A

P698

Q30531601-7406C916-80E0-41CF-9A24-92C39FAA9A89

P932

Q30531601-ABC13760-08B6-4E66-A287-1465E1E727FF

P356

P1433

Molecular Therapy

P1476

Cerebral infusion of AAV9 vect ...... ell-mediated immune responses.

@en

P2093

Agnieszka Ciesielska

http://www.w3.org/2001/XMLSchema#string

Gabriele Mittermeyer

http://www.w3.org/2001/XMLSchema#string

J Fraser Wright

http://www.w3.org/2001/XMLSchema#string

John Forsayeth

http://www.w3.org/2001/XMLSchema#string

Krystof S Bankiewicz

http://www.w3.org/2001/XMLSchema#string

Piotr Hadaczek

http://www.w3.org/2001/XMLSchema#string

Shangzhen Zhou

http://www.w3.org/2001/XMLSchema#string

P2860

Safety and tolerability of putaminal AADC gene therapy for Parkinson disease

Optimized cannula design and placement for convection-enhanced delivery in rat striatum

Fluoro-jade B stains quiescent and reactive astrocytes in the rodent spinal cord.

Adeno-associated virus vectors can be efficiently produced without helper virus.

Fluoro-Jade B staining as useful tool to identify activated microglia and astrocytes in a mouse transgenic model of Alzheimer's disease.

Results from a phase I safety trial of hAADC gene therapy for Parkinson disease.

Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates

Recombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vector.

Recombinant AAV-mediated gene delivery to the central nervous system.

Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates

P304

158-166

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2012.167

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230755739

http://www.w3.org/2001/XMLSchema#string

P698

22929660

http://www.w3.org/2001/XMLSchema#string

P932

3538301

http://www.w3.org/2001/XMLSchema#string